糖尿病视网膜病变的病理生理学研究进展

doi:10.3969/j.issn.1006-7795.2023.03.010

首都医科大学学报 ›› 2023, Vol. 44 ›› Issue (3): 420-423.doi: 10.3969/j.issn.1006-7795.2023.03.010

• 泌尿生殖系统肿瘤临床研究 • 上一篇下一篇

糖尿病视网膜病变的病理生理学研究进展

冯晓彤^#，柯静^#，朱琳，赵冬^*

首都医科大学附属北京潞河医院内分泌代谢与免疫性疾病中心糖尿病防治研究北京市重点实验室，北京 101149

收稿日期:2023-03-01 出版日期:2023-06-21 发布日期:2023-06-06
通讯作者: 赵冬 E-mail:zhaodong@ccmu.edu.cn
基金资助:
北京市自然科学基金项目（7222099）

Progress in the pathophysiology of diabetes retinopathy

Feng Xiaotong^#, Ke Jing^#, Zhu Lin, Zhao Dong^*

Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing Key Laboratory of Diabetes Research and Care, Beijing 101149, China

Received:2023-03-01 Online:2023-06-21 Published:2023-06-06
Supported by:
This study was supported by Natural Science Foundation of Beijing (7222099)

摘要/Abstract

摘要： 糖尿病视网膜病变（diabetic retinopathy, DR）是导致成人失明的重要原因之一，严重威胁糖尿病患者的生存质量，同时给社会带来了沉重的经济负担，既往研究已表明神经血管单元（neurovascular unit, NVU）损害是DR发生发展的关键环节，包括视网膜血管内皮细胞损伤、细胞间紧密连接受损、周细胞丢失、内皮细胞－周细胞相互作用的破坏等多个方面。

关键词: 糖尿病, 糖尿病视网膜病变, 血管神经单元

Abstract: Diabetic retinopathy (DR), one of the important causes of blindness in adults, seriously threatens the life quality of patients with diabetes mellitus and brings heavy economic burden to the society. Previous studies have shown that the impairment of neurovascular unit (NVU) plays an important role in the occurrence and development of DR, including retinal vascular endothelial cells damage, impairment of cell junctions, loss of pericytes, pericyte-endothelial cells communication impairment and so on.

Key words: diabetes mellitus, diabetic retinopathy, neurovascular unit

中图分类号:

冯晓彤, 柯静, 朱琳, 赵冬. 糖尿病视网膜病变的病理生理学研究进展[J]. 首都医科大学学报, 2023, 44(3): 420-423.

Feng Xiaotong, Ke Jing, Zhu Lin, Zhao Dong. Progress in the pathophysiology of diabetes retinopathy[J]. Journal of Capital Medical University, 2023, 44(3): 420-423.

参考文献

［1］Hou Y Y, Cai Y T, Jia Z M, et al. Risk factors and prevalence of diabetic retinopathy: a protocol for meta-analysis［J］. Medicine (Baltimore), 2020, 99(42): e22695.
［2］Chua J, Lim C X Y, Wong T Y, et al. Diabetic retinopathy in the Asia-Pacific［J］. Asia Pac J Ophthalmol (Phila), 2018, 7(1): 3－16.
［3］Cheung N, Mitchell P, Wong T Y. Diabetic retinopathy［J］. Lancet, 2010, 376(9735): 124－136.
［4］Solomon S D, Chew E, Duh E J, et al. Diabetic retinopathy: a position statement by the American diabetes association［J］. Diabetes Care, 2017, 40(3): 412－418.
［5］Antonetti D A, Silva P S, Stitt A W. Current understanding of the molecular and cellular pathology of diabetic retinopathy［J］. Nat Rev Endocrinol, 2021, 17(4): 195－206.
［6］Simó R, Stitt A W, Gardner T W. Neurodegeneration in diabetic retinopathy: does it really matter?［J］. Diabetologia, 2018, 61(9): 1902－1912.
［7］Klaassen I, Van Noorden C J F, Schlingemann R O. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions［J］. Prog Retin Eye Res, 2013, 34: 19－48.
［8］Brownlee M. The pathobiology of diabetic complications: a unifying mechanism［J］. Diabetes, 2005, 54(6): 1615－1625.
［9］Uribarri J, Stirban A, Sander D, et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects［J］. Diabetes Care, 2007, 30(10): 2579－2582.
［10］Limb G A, Hickman-Casey J, Hollifield R D, et al. Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy［J］. Invest Ophthalmol Vis Sci, 1999, 40(10): 2453－2457.
［11］Mizutani M, Kern T S, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy［J］. J Clin Invest, 1996, 97(12): 2883－2890.
［12］Wei L F, Mo W W, Lan S S, et al. GLP-1 RA improves diabetic retinopathy by protecting the blood-retinal barrier through GLP-1R-ROCK-p-MLC signaling pathway［J］. J Diabetes Res, 2022, 2022: 1861940.
［13］Ting K K, Zhao Y, Shen W Y, et al. Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models［J］. Diabetologia, 2019, 62(2): 322－334.
［14］Trost A, Lange S, Schroedl F, et al. Brain and retinal pericytes: origin, function and role［J］. Front Cell Neurosci, 2016, 10: 20.
［15］Ogura S, Kurata K, Hattori Y, et al. Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown［J］. JCI Insight, 2017, 2(3): e90905.
［16］Eshaq R S, Aldalati A M Z, Alexander J S, et al. Diabetic retinopathy: breaking the barrier［J］. Pathophysiology, 2017, 24(4): 229－241.
［17］Eleftheriou C G, Ivanova E, Sagdullaev B T. Of neurons and pericytes: the neuro-vascular approach to diabetic retinopathy［J］. Vis Neurosci, 2020, 37: E005.
［18］Hammes H P, Feng Y X, Pfister F, et al. Diabetic retinopathy: targeting vasoregression［J］. Diabetes, 2011, 60(1): 9－16.
［19］Ivanova E, Kovacs-Oller T, Sagdullaev B T. Vascular pericyte impairment and connexin43 gap junction deficit contribute to vasomotor decline in diabetic retinopathy［J］. J Neurosci, 2017, 37(32): 7580－7594.
［20］Pfister F, Feng Y, Vom Hagen F, et al. Pericyte migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy［J］. Diabetes, 2008, 57(9): 2495－2502.
［21］Huang H. Pericyte-endothelial interactions in the retinal microvasculature［J］. Int J Mol Sci, 2020, 21(19): 7413.
［22］Middel C S, Hammes H P, Kroll J. Advancing diabetic retinopathy research: analysis of the neurovascular unit in zebrafish［J］. Cells, 2021, 10(6): 1313.
［23］Eilken H M, Diéguez-Hurtado R, Schmidt I, et al. Pericytes regulate VEGF-induced endothelial sprouting through VEGFR1［J］. Nat Commun, 2017, 8(1): 1574.
［24］Hammes H P. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond［J］. Diabetologia, 2018, 61(1): 29－38.
［25］Nian S, Lo A C Y, Mi Y J, et al. Neurovascular unit in diabetic retinopathy: pathophysiological roles and potential therapeutical targets［J］. Eye Vis (Lond), 2021, 8(1): 15.
［26］Kinuthia U M, Wolf A, Langmann T. Microglia and inflammatory responses in diabetic retinopathy［J］. Front Immunol, 2020, 11: 564077.
［27］Mugisho O O, Rupenthal I D, Squirrell D M, et al. Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: modelling signs of diabetic retinopathy［J］. PLoS One, 2018, 13(8): e0202156.

[1]	刘畅, 郭默宁, 袁颖超, 郑建鹏, 杨金奎. 2013至2018年北京地区1型糖尿病发病率性别差异及预测[J]. 首都医科大学学报, 2023, 44(3): 370-374.
[2]	李雨阳, 朱晓蓉, 刘婧, 郑晓敏, 杨金奎, 杨芳远. 糖尿病肾病患者触珠蛋白基因多态性及血清触珠蛋白浓度分析[J]. 首都医科大学学报, 2023, 44(3): 375-380.
[3]	郑晓敏, 李彬, 刘翠平, 周迎生, 崔丽梅. 老年2型糖尿病患者黎明现象的分析和对策[J]. 首都医科大学学报, 2023, 44(3): 400-406.
[4]	李明嘉, 赵苗妙, 杨金奎. 组织蛋白酶在糖尿病及糖尿病肾病作用机制中的研究进展[J]. 首都医科大学学报, 2023, 44(3): 413-419.
[5]	夏宁, 聂秀红, 王美平, 冯志红, 穆志静, 樊晓君. 阻塞性睡眠呼吸暂停与单纯鼾症患者的睡眠效率与糖尿病患病率的相关性研究[J]. 首都医科大学学报, 2023, 44(3): 487-496.
[6]	马玉茹, 袁仙仙, 郑薇, 刘程, 王佳, 李光辉. 妊娠早期血清游离脂肪酸水平与妊娠期糖尿病的关系[J]. 首都医科大学学报, 2023, 44(2): 265-271.

糖尿病视网膜病变的病理生理学研究进展

Progress in the pathophysiology of diabetes retinopathy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

本文评价